Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) is a medical device company focused on device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine. This news page aggregates company-issued updates and market-moving announcements related to ClearPoint Neuro’s neurosurgical navigation systems, laser therapy platforms, intracranial fluid management technologies, and central nervous system drug delivery services.
Readers can follow earnings and financial updates, such as preliminary unaudited revenue results and quarterly reports furnished via Form 8-K, which outline trends in biologics and drug delivery revenue, neurosurgery navigation and therapy revenue, and capital equipment and software sales. News items also cover strategic transactions, including the completed acquisition of IRRAS Holdings, Inc., which adds the IRRAflow active fluid-exchange system and expands ClearPoint Neuro’s presence in neurocritical care and intracranial bleeding management.
ClearPoint Neuro’s news flow frequently highlights regulatory milestones like FDA 510(k) clearances, including expanded MRI compatibility for the ClearPoint Prism Neuro Laser Therapy System, and international regulatory approvals that extend product use to additional countries. The company also reports on clinical and scientific developments, such as Phase I–II study results in glioblastoma and grade 4 astrocytoma using ClearPoint Prism, as well as the development and demonstration of its proprietary Robotic Neuro-Navigation System.
Investors and observers can also track partnership and conference activity, including updates on more than 60 active biopharma partners, participation in global healthcare conferences, and progress at ClearPoint Advanced Laboratories. Bookmark this page to review historical and ongoing CLPT news related to neurosurgical devices, therapy delivery platforms, and the company’s role in enabling cell and gene therapy programs.
ClearPoint Neuro has announced a significant milestone as partner PTC Therapeutics receives marketing authorization from the European Commission for Upstaza™, the first gene therapy approved for direct infusion into the brain. This therapy targets aromatic L-amino acid decarboxylase (AADC) deficiency, a severe condition affecting children, and is now authorized for patients aged 18 months and older across the EU and select countries. ClearPoint's SmartFlow® Neuro Cannula will be utilized in administering this therapy, enhancing the treatment landscape for neurological disorders.
ClearPoint Neuro (CLPT) congratulated partner Neurona Therapeutics for administering the first dose in their Phase 1/2 clinical trial of NRTX-1001, aimed at treating mesial temporal lobe epilepsy (MTLE). This innovative regenerative neural cell therapy could address a significant unmet need as 25-35% of epilepsy patients experience ongoing seizures despite existing treatments. The trial will include an open-label dose-escalation study involving up to 10 patients. ClearPoint continues to expand its role in enabling novel therapies for complex neurological disorders.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced its certification for the Medical Device Single Audit Program (MDSAP) on June 2, 2022. This certification allows a single regulatory audit to satisfy requirements from multiple jurisdictions, including the U.S. FDA and authorities in Australia, Brazil, Canada, and Japan. Megan Faulkenberry, VP of Quality and Regulatory, highlighted this milestone as crucial for the company's global expansion strategy. ClearPoint's mission focuses on improving patient outcomes through accurate delivery of therapies for neurological disorders.
ClearPoint Neuro has announced a significant milestone as PTC Therapeutics receives a positive opinion from the European Medicines Agency for its gene therapy, Upstaza, to treat AADC deficiency. This marks the first gene therapy to be administered directly into the brain using ClearPoint's SmartFlow® Cannula. ClearPoint’s CEO, Joe Burnett, emphasized that this recommendation validates their biologics partnership strategy and sets a precedent for future brain-targeted therapies. The SmartFlow Cannula has over 5,000 units sold and is key in bypassing the blood-brain barrier for therapeutics.
ClearPoint Neuro announced its first-time presentation at the 25th Annual Meeting of the American Society of Gene & Cell Therapy on May 16, 2022. The session will showcase investigational research on gene therapy delivery methods using convection-enhanced delivery. Dr. Ernesto Salegio will present findings in a poster titled AAV Vectors - Preclinical and Proof-of-Concept. ClearPoint aims to demonstrate the feasibility of its technology for targeting and delivering gene therapies while emphasizing the importance of real-time MRI visualization for monitoring.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) reported a record Q1 2022 revenue of $5.0 million, marking a 25% year-over-year increase. The growth was driven by a 30% rise in biologics and drug delivery revenue to $2.2 million. The company expanded its global presence with four additional sites and partnered with Philips for advanced operating room technology. Full-year revenue is now projected between $21.0 million and $22.0 million, translating to a 30-35% growth compared to 2021. Operating expenses rose to $7.1 million, influenced by increased headcount and development costs.
ClearPoint Neuro (CLPT) announces a collaboration with Higgs Boson Health to develop the MyClearPoint™ digital health app. This app aims to enhance drug delivery to the brain and spine and support brain-computer interface surgeries. It will provide patients with essential services, including education and recovery tracking. The partnership leverages Higgs Boson’s proven ManageMySurgery platform, which has shown to improve surgical outcomes and reduce cancellations. This initiative is poised to reduce healthcare resource utilization and improve patient satisfaction.
ClearPoint Neuro has received FDA clearance for version 1.1 of its SmartFrame Array Neuro Navigation System, designed to improve procedures in MRI suites and operating rooms. The system, in limited market release since May 2021, has been utilized in over 50 procedures across 10 clinical sites. The new version includes a pre-planning module to enhance workflow and reduce procedure time. The company's mission focuses on enabling therapies for complex neurological disorders. The SmartFrame Array's enhanced features aim to streamline clinical trial processes.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced an expansion of its licensing agreement with Philips to incorporate Computed Tomography (CT) into its surgical navigation system. This aims to enhance surgical procedures in the Operating Room (OR), utilizing the ClearPoint Maestro™ Brain Model for improved accuracy. The integration will facilitate the training of surgeons and allow workflows to mirror those used in MRI environments. ClearPoint's navigation system has FDA clearance and is operational in around 60 sites globally, supporting various neurological treatments.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced it will release its financial results for Q1 2022 on May 11, 2022, post-market. Investors can join a live review at 4:30 p.m. ET the same day via a conference call or online. The company focuses on enabling therapies for complex neurological disorders and has FDA clearance for its ClearPoint® Neuro Navigation System, operational in approximately 60 sites across the US, Canada, and Europe. ClearPoint is also engaged with about 40 biologics/pharmaceutical firms for CNS therapeutic delivery.